ASCENDEX
3.11.2021 20:58:03 CET | Business Wire | Press release
AscendEX , a global cryptocurrency financial platform, has announced the close of a $50 million Series B raise led by Polychain Capital and Hack VC , with participation from Jump Capital and Alameda Research , as well as Uncorrelated Ventures , Eterna Capital , Acheron Trading , Nothing Research , and Palm Drive Capital . Imperii Partners served as an exclusive financial advisor to AscendEX in support of the Series B fundraise process.
AscendEX, launched under the name “BitMax” in July 2018, offers exchange, custody, and staking services to over one million retail and institutional clients globally. The platform has positioned itself as an infrastructure partner to blockchain companies, specifically in the decentralized finance (“DeFi”) sector, and operates as a validator and yield farming portal for over 60 token projects.
“We are grateful to have very prominent investors involved in our latest fundraising round, ” said George Cao, CEO and Co-founder of AscendEX. “Polychain Capital and Hack VC, as active catalysts of the DeFi ecosystem, have backed some of the industry’s most innovative blockchain networks, exchanges, and trading institutions. Similarly, Alameda Research, founded by Sam Bankman-Fried, has emerged as one of the most prolific investors in the industry, fueling growth within both CeFi and DeFi. Participation from Jump Capital, a seasoned Crypto and Fintech investor, further showcases the success of our deep roots in traditional finance, as AscendEX’s core team is proud of our extensive experience in Wall Street quant trading.”
AscendEX is well positioned at the nexus between centralized & decentralized financial sectors, as evidenced by its AscendEX Earn products, and cross-collateralized staking products that allow users to generate yield while trading on leverage. By empowering retail and institutional users to maximize their trading and earning potential, AscendEX has achieved over $200 million in average daily trade volume and provides competitive yields among competing centralized exchanges.
“AscendEX plans to use the Series B funds to accelerate international market entry, and catalyze further product innovation, specifically focused on blockchain-based yield generating protocols,” notes Shane Molidor, Global Head of Business Development at AscendEX. “Building a bridge to the DeFi ecosystem has allowed AscendEX to differentiate itself from other cryptocurrency exchanges and has made the platform a popular destination for innovative DeFi projects to conduct initial exchange offerings (“IEOs”). We are thrilled to collaborate with our new investors to further solidify our unique competitive advantages.”
Sam Trabucco, Co-CEO of Alameda Research, added, “Alameda has had nothing but great experiences working with AscendEX as a customer and market maker, and we’re thrilled to keep expanding our relationship in new ways with this investment.”
“AscendEX is a leader in transitioning crypto projects from primary to secondary markets, as seen through the continued success of the tokens listed on the exchange, ” said Olaf Carlson-Wee, Founder & CEO at Polychain Capital. “We look forward to deepening our collaboration with AscendEX by providing insights into evolving industry trends and providing guidance on top-tier projects to list on the exchange.”
AscendEX uniquely provides dedicated auxiliary support for blockchain projects seeking to list on the platform, including consultation on the token economic design, secondary market liquidity strategies, staking support, liquidity mining, as well as global marketing support and translation services. These supporting services further differentiate AscendEX’s IEO process from other mainstream exchanges, and in turn, allow listings to achieve industry leading results.
"In an extremely competitive crypto exchange landscape, AscendEX has impressively emerged as the leading venue for innovative crypto projects in DeFi, GameFi and crypto infrastructure , " said Saurabh Sharma, Partner at Jump Capital. "AscendEX remains ahead of the curve by constantly innovating and offering unmet needs such as broad staking access and DeFi yield farming for retail investors."
Alex Pack at Hack VC added, “The concept of extracting more value from the crypto held in your wallet has become immensely popular with decentralized lending and yield farming protocol – AscendEX has further expanded on this by cross-collateralizing their wallets with validator nodes, allowing users to trade while earning. No other exchange is offering this degree of flexibility for users to earn and participate in blockchain governance while also trading on leverage.”
To learn more about AscendEX, please visit AscendEX.com .
About AscendEX
AscendEX is a global cryptocurrency financial platform servicing more than one million institutional and retail traders with the resources needed to obtain more value from their crypto investments. Operating at the nexus of centralized finance and decentralized finance, AscendEX’s platform features access to futures and spot trading, a robust wallet infrastructure, and staking support for over 200 industry-leading blockchain projects, all producing industry leading yields and returns, further driving the growth of the crypto ecosystem. In efforts to cultivate scalable and secure forms of decentralized financing, AscendEX has emerged as a leading platform by ROI on its “initial exchange offerings” through supporting some of the industry’s most innovative projects from the DeFi ecosystem. To learn more about how AscendEX leverages best practices from both Wall Street and the cryptocurrency ecosystem to extract the highest value per dollar to its users, please visit www.AscendEX.com
.
About Polychain Capital
The emergence of bitcoin and subsequent blockchain technologies has generated a new digital asset class in which scarcity is based on mathematical properties. Through cryptographic verification and game-theoretic equilibrium, blockchain-based digital assets can be created, issued, and transmitted using software. Polychain is an investment firm committed to exceptional returns for investors through actively managed portfolios of these blockchain assets.
About Hack VC
Hack VC is a private equity firm based in Incline Village, Nevada.
About Alameda Research
Alameda Research was founded in October 2017. We manage over $1 billion in digital assets and trade $1-10 billion per day across thousands of products: all major coins and altcoins, as well as their derivatives. We have a full-scale global operation with the ability to trade on all major exchanges and markets.
About Jump Capital
Jump Capital is a leading venture fund investing in Crypto and Fintech globally.
About Uncorrelated Ventures
Uncorrelated Ventures was founded by Salil Deshpande with Bain's backing to focus on open source and infrastructure software, both traditional and decentralized. Over 14 years as general partner and managing director at Bay Partners and Bain Capital, Salil invested $350M+ into 50+ companies early. Additionally, Salil was on the Forbes Midas List of the 100 best-performing venture investors worldwide in 2013 – 2019, and Business Insider's inaugural Seed-100 list of the 100 best-performing seed investors in 2021.
About Eterna Capital
Eterna Capital is a UK-based venture capital fund focused on backing bold, innovative teams that harness the power of blockchain. Launched in March of 2018, Eterna has invested in numerous high profile deals and is committed to helping entrepreneurs reach their ambitious goals by providing unique insights and support.
About Acheron Trading
Acheron Trading is a designated market maker building liquid markets for digital assets. We trade on centralized and decentralized exchanges worldwide with over $250 million in assets under management.
About Nothing Research
Nothing Research is a multi-strategy venture firm investing in open finance initiatives. It was founded in March 2021 by a group of digital asset market veterans with professional backgrounds from research institutes, hedge funds and leading digital asset trading platforms such as Huobi and AscendEX. It differentiates itself with its desirability to build alongside founders and shapes narratives together with invested projects.
About Palm Drive Capital
Palm Drive Capital is a New York, and Miami-based venture capital and growth equity fund that has invested in over 100 leading software and internet companies around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom